158 related articles for article (PubMed ID: 37882432)
21. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y
Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772
[TBL] [Abstract][Full Text] [Related]
22. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
[TBL] [Abstract][Full Text] [Related]
23. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Rustum YM; Chintala S; Durrani FA; Bhattacharya A
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
[TBL] [Abstract][Full Text] [Related]
24. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Hirsch L; Flippot R; Escudier B; Albiges L
Drugs; 2020 Aug; 80(12):1169-1181. PubMed ID: 32601914
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
Ged Y; Gupta R; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Voss MH; Feldman DR; Akin O; Patil S; Motzer RJ; Rini BI; Lee CH
BMC Urol; 2020 Jul; 20(1):84. PubMed ID: 32616076
[TBL] [Abstract][Full Text] [Related]
29. Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ahmed R; Ornstein MC
Curr Treat Options Oncol; 2023 Sep; 24(9):1183-1198. PubMed ID: 37403008
[TBL] [Abstract][Full Text] [Related]
30. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
31. The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma.
Srivastava A; Doppalapudi SK; Patel HV; Srinivasan R; Singer EA
Curr Opin Oncol; 2022 May; 34(3):234-242. PubMed ID: 35266906
[TBL] [Abstract][Full Text] [Related]
32. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Rha SY; Choueiri TK; Matveev VB; Alyasova A; Hong SH; Gordoa TA; Gurney H; Bjarnason GA; Buchler T; Pedrazzoli P; Takagi T; Park SH; Lee JL; Perini RF; He CS; McKenzie JA; Eto M
Int J Cancer; 2023 Sep; 153(6):1241-1250. PubMed ID: 37294085
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Perets R; Bar J; Rasco DW; Ahn MJ; Yoh K; Kim DW; Nagrial A; Satouchi M; Lee DH; Spigel DR; Kotasek D; Gutierrez M; Niu J; Siddiqi S; Li X; Cyrus J; Chackerian A; Chain A; Altura RA; Cho BC
Ann Oncol; 2021 Mar; 32(3):395-403. PubMed ID: 33276076
[TBL] [Abstract][Full Text] [Related]
36. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
[TBL] [Abstract][Full Text] [Related]
39. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
Atkins MB; Tannir NM
Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]